Among them, KRAS-mutant lung adenocarcinomas with TP53 inactivation is characterized as high PD-L1 expression together with high TMB and marked T-cell infiltration, and showing favorable responses to monotherapy with anti-PD-1/PD-L1 antibodies [23,24]. This evidence concerns the gene KRAS and lung adenocarcinoma.